Scipher Medicine is driving the probability of success at each stage of drug development from discovery to commercialization by leveraging AI with network biology, and proprietary data, through our SPECTRA Rx and Dx platforms. Scipher has the industry's largest non-oncology clinico-genomic data asset and biobank in addition to EMR data for over 3 million rheumatology patients.
Collaboration combines Scipher’s unique RNAseq data with InnoSIGN’s proprietary comprehensive pathway analysis (CPA) platform to enhance the understanding of complex immune-mediated diseases.